<DOC>
	<DOC>NCT01150903</DOC>
	<brief_summary>Erectile dysfunction (ED) has been identified as an independent risk factor for existing cardiovascular disease, preceding a major cardiovascular event by an average of about 5 years. Are men prescribed a PDE5 inhibitor for ED more likely to have a new diagnosis of underlying medical conditions compared to men of a similar age not receiving PDE5 inhibitor treatment?</brief_summary>
	<brief_title>Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Records of men aged &gt;18 years with an index PDE5 inhibitor (sildenafil, tadalafil or vardenafil) prescription between January 1st, 1999, and June 30th, 2008 no prior PDE5 inhibitor prescription before the index prescription continuous enrolment with medical history for â‰¥60 months prior to the index prescription date Records of female subjects and any male subjects not meeting the inclusion criteria will be excluded A subject can only be selected once independent of the assignment to the target or the control populations.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>erectile dysfunction</keyword>
	<keyword>phosphodiesterase inhibitor</keyword>
	<keyword>cardiovascular diseases</keyword>
</DOC>